Wang, Zhao <br/><br/>
Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study.  [electronic resource] 

 -  Leukemia & lymphoma  12 2018 
 - 2821-2828 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2018.1459605  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Cytarabine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Lymphoma, Non-Hodgkin--blood<br/>Male<br/>Middle Aged<br/>Platelet Count<br/>Platelet Transfusion--statistics & numerical data<br/>Prospective Studies<br/>Recombinant Proteins--administration & dosage<br/>Thrombocytopenia--blood<br/>Thrombopoietin--administration & dosage<br/>Treatment Outcome<br/>Young Adult